| Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström Journal of pharmacokinetics and pharmacodynamics 33 (1), 75-91, 2006 | 58 | 2006 |
| Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ... Pharmaceutical research 14 (2), 176-180, 1997 | 58 | 1997 |
| Modelling a spontaneously reported side effect by use of a Markov mixed-effects model PH Zingmark, M Kågedal, MO Karlsson Journal of pharmacokinetics and pharmacodynamics 32 (2), 261-281, 2005 | 46 | 2005 |
| A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ... Neuroimage 82, 160-169, 2013 | 43 | 2013 |
| Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013 | 32 | 2013 |
| Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C … K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ... Psychopharmacology 213 (2-3), 533-545, 2011 | 26 | 2011 |
| Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ... NeuroImage 61 (4), 849-856, 2012 | 24 | 2012 |
| Distribution of zolmitriptan into the CNS in healthy volunteers A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ... Drugs in R & D 6 (3), 139-147, 2005 | 23 | 2005 |
| PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ... European Neuropsychopharmacology 18, S270-S270, 2008 | 21 | 2008 |
| Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ... CPT: pharmacometrics & systems pharmacology 6 (6), 401-408, 2017 | 19 | 2017 |
| Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results from the Phase Ib Dose‐Finding Study WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ... The Journal of Clinical Pharmacology 59 (5), 702-716, 2019 | 18 | 2019 |
| True nasopharangeal absorption of zolmitriptan following administration of zolmitriptan nasal spray PH Zingmark, R Yates, C Hedlund, M Kagedal European Journal of Neurology Supplement 10, 2003 | 16 | 2003 |
| Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz European Journal of Pain 17 (10), 1465-1471, 2013 | 14 | 2013 |
| Safety Evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorder L Ståhle, R Karlsten, B Jonzon, B Eriksson, M Kågedal, A Dominicus 14th World Congress on Pain, 27-31, 2012 | 10 | 2012 |
| Early phase drug development for treatment of chronic pain—Options for clinical trial and program design J Kalliomäki, F Miller, M Kågedal, R Karlsten Contemporary clinical trials 33 (4), 689-699, 2012 | 10 | 2012 |
| Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study WP Kirschbrown, M Kågedal, B Wang, L Lindbom, A Knott, R Mack, ... Cancer chemotherapy and pharmacology 83 (6), 1147-1158, 2019 | 9 | 2019 |
| Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates M Kågedal, L Gibiansky, J Xu, X Wang, D Samineni, SC Chen, D Lu, ... Journal of pharmacokinetics and pharmacodynamics 44 (6), 537-548, 2017 | 8 | 2017 |
| Autoradiographic mapping of 5-HT1B/1D binding sites in the rhesus monkey brain using [carbonyl-11C] zolmitriptan Ö Lindhe, P Almqvist, M Kågedal, SÅ Gustafsson, M Bergström, D Nilsson, ... International journal of molecular imaging 2011, 2011 | 8 | 2011 |
| Differential sensitivity of gastric and small intestinal muscles to inducible knockdown of anoctamin 1 and the effects on gastrointestinal motility SJ Hwang, DM Pardo, H Zheng, Y Bayguinov, PJ Blair, R Fortune‐Grant, ... The Journal of physiology 597 (9), 2337-2360, 2019 | 7 | 2019 |
| A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ... Journal of clinical pharmacology 47 (8), 1043-1049, 2007 | 7 | 2007 |
Andrew C. HookerAssociate Professor of Pharmacometrics, Uppsala UniversityVerified email at farmbio.uu.se
